- Home
- CRBP vs SPPP Comparison
CRBP vs SPPP Comparison
Compare CRBP & SPPP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CRBP
- SPPP
- Stock Information
- Founded
- CRBP 2009
- SPPP 2011
- Country
- CRBP United States
- SPPP Canada
- Employees
- CRBP 19
- SPPP N/A
- Industry
- CRBP Biotechnology: Pharmaceutical Preparations
- SPPP
- Sector
- CRBP Health Care
- SPPP
- Exchange
- CRBP Nasdaq
- SPPP NYSE
- Market Cap
- CRBP 158.3M
- SPPP 139.1M
- IPO Year
- CRBP N/A
- SPPP N/A
- Fundamental
- Price
- CRBP $13.00
- SPPP $9.04
- Analyst Decision
- CRBP Strong Buy
- SPPP
- Analyst Count
- CRBP 8
- SPPP 0
- Target Price
- CRBP $62.00
- SPPP N/A
- AVG Volume (30 Days)
- CRBP 313.3K
- SPPP 274.1K
- Earning Date
- CRBP 11-07-2024
- SPPP 01-01-0001
- Dividend Yield
- CRBP N/A
- SPPP N/A
- EPS Growth
- CRBP N/A
- SPPP N/A
- EPS
- CRBP N/A
- SPPP N/A
- Revenue
- CRBP N/A
- SPPP N/A
- Revenue This Year
- CRBP N/A
- SPPP N/A
- Revenue Next Year
- CRBP N/A
- SPPP N/A
- P/E Ratio
- CRBP N/A
- SPPP N/A
- Revenue Growth
- CRBP N/A
- SPPP N/A
- 52 Week Low
- CRBP $5.25
- SPPP $8.55
- 52 Week High
- CRBP $61.90
- SPPP $11.39
- Technical
- Relative Strength Index (RSI)
- CRBP 25.10
- SPPP 33.49
- Support Level
- CRBP $12.90
- SPPP $9.22
- Resistance Level
- CRBP $16.21
- SPPP $9.37
- Average True Range (ATR)
- CRBP 0.95
- SPPP 0.13
- MACD
- CRBP -0.16
- SPPP -0.02
- Stochastic Oscillator
- CRBP 1.69
- SPPP 15.07
About CRBP Corbus Pharmaceuticals Holdings Inc.
Corbus Pharmaceuticals Holdings Inc is a precision oncology company with a diversified portfolio and is committed to helping people defeat serious illness by bringing scientific approaches to well-understood biological pathways. The company's development pipeline includes; CRB-701, a next-generation antibody-drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload, CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGF expressed on cancer cells, and CRB-913 a second-generation peripherally restricted CB1 receptor inverse agonist designed to treat obesity.
About SPPP SPROTT PHYS PLATINUM & PALLADIUM
Sprott Physical Platinum & Palladium Tr invests and holds all of its assets in physical platinum and palladium bullion. The company seeks to provide a secure, convenient, and exchange-traded investment alternative for investors interested in holding physical platinum and palladium bullion without the inconvenience that is typical of a direct investment in physical bullion. The Trust invests mainly in long-term holdings of unencumbered, fully allocated, physical platinum and palladium bullion.